Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
June 5, 2026 06:30 PM EDT
Roche’s incretin shot works in mid-stage trial in type 1 diabetes
Elizabeth Cairns
Senior biopharma journalist
A daily incretin shot being developed by Roche has shown promise in type 1 diabetes — the form that is not generally believed to be directly …
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
Daily tablet could transform type 2 diabetes treatment, trial finds
Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
Next-generation automated insulin delivery algorithm raises time in range in diabetes
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes—presented at ADA 2026
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in…
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes,…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and…
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs…
Teplizumab can allow patients to live “normal lives” without the need for insulin injections
